GE HealthCare Technologies Inc

GE Healthcare Technologies, Inc. operates as a holding company with interest in providing medical technology, pharmaceutical diagnostics and digital solutions. Its operating segments include Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Ultrasound segment offers screening, diagnosis, treatment and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company was founded on May 16, 2022 and is headquartered in Chicago, IL.

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GE HealthCare posts robust Q4 results, eyes growth opportunities

GE HealthCare Technologies Inc delivered a strong Q4 2022 performance with notable organic revenue growth and margin expansion.
While facing challenges such as COVID-related impacts and debt interest, the company is well-positioned for growth through pricing strategies and market demand.
Opportunities lie in continued revenue growth, margin expansion, and product innovations, supported by strong market demand and strategic initiatives.
Overall, GE HealthCare's focus on performance improvement, innovation, and financial discipline sets a positive trajectory for future growth and competitiveness.

GE HealthCare reports robust Q1 earnings, eyes growth opportunities

GE HealthCare Technologies Inc delivered strong financial results in Q1 2023, with revenue growth, margin improvement, and reaffirmed guidance for the full year. The company's focus on innovation, technology investments, and strategic acquisitions positions it well for future growth.

GE HealthCare reports strong Q2 earnings, eyes precision care growth

GE HealthCare Technologies delivered strong financial performance in Q2 2023, driven by revenue growth, innovation in AI technologies, and strategic investments in key segments.
While facing challenges such as margin improvements and geopolitical risks, the company remains focused on capitalizing on growth opportunities in precision care and technological advancements.
Executives emphasized a balanced approach to capital allocation, margin expansion, and long-term growth strategies, positioning GEHC for sustained success in the evolving healthcare landscape.
Overall, GEHC's Q2 earnings call highlighted a resilient business outlook, with a clear focus on driving innovation, enhancing margins, and seizing opportunities for growth and market leadership.

GE HealthCare reports solid Q3 growth, eyes opportunities amid challenges

GE HealthCare Technologies Inc reported strong Q3 2023 performance with revenue growth, margin expansion, and strategic collaborations.
The company faces challenges in capital spending sentiment, margin targets, and managing balance sheet risks.
Opportunities for growth include new product launches, market focus, and upcoming investor engagements.
Overall, GEHC's resilience, operational improvements, and growth strategies position it well for future success.

GE HealthCare reports robust earnings, eyes growth through innovation

GE HealthCare Technologies Inc delivered strong financial performance in Q4 2023 and full-year 2023, driven by organic growth, strategic acquisitions, and margin expansion initiatives.
While facing challenges such as anticipated market declines and macroeconomic uncertainties, the company is well-positioned to leverage opportunities in increased demand, innovative technologies, and strategic partnerships.
By focusing on driving value through innovation, sustainability, and strategic investments, GE HealthCare is poised for continued growth and market leadership in the healthcare technology sector.
The outlook for 2024 indicates a positive trajectory with anticipated revenue growth, margin expansion, and a commitment to delivering high-value solutions to customers, supported by a strong financial foundation.

GE Healthcare reports steady Q1 performance amidst global challenges

GE Healthcare Technologies showcased a mixed performance in Q1 2024, with flat organic revenue growth and varied segment results.
The company remains focused on strategic alliances, margin initiatives, and cost savings to support EBIT expansion and solid margin performance.
Challenges in China sales and the need for clarity on the stimulus package present uncertainties, while opportunities lie in segment growth and new product introductions.

GE HealthCare reports steady Q2 growth amidst China challenges

GE HealthCare Technologies Inc delivered solid Q2 performance with growth in key segments like Patient Care Solutions and Pharmaceutical Diagnostics. Despite challenges in China, the company remains focused on driving margin expansion and innovation for sustained growth.

GE HealthCare reports steady Q3 growth amidst China market challenges

GE HealthCare Technologies Inc delivered a solid financial performance in Q3 2024, with 1% organic revenue growth and strong margin performance.
While facing challenges in the slow recovery of the China market, the company showcased strengths in free cash flow generation and technological innovations.
Future opportunities lie in margin expansion, growth initiatives like Flyrcado and AI solutions, and market differentiation through innovative healthcare technologies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GE Healthcare Technologies, Inc. engages in the development and manufacturing of medical technology, pharmaceutical diagnostics, and digital solutions. It operates through the following segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Ultrasound segment offers screening, diagnosis, treatment, and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services, and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company’s history roots back to the year 1892 and it was incorporated on May 16, 2022 and is headquartered in Chicago, IL.

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Today Heart Hospital of New Mexico at Lovelace Medical Center (HHNM) and GE HealthCare (Nasdaq: GEHC) announced HHNM as the first location in the United States to install GE HealthCare's latest Allia Image Guided System (IGS) Pulse, which was designed to provide exceptional image quality and improve workflow for the diagnosis and treatment of cardiovascular diseases (CVD). HHNM will use the Allia IGS Pulse system in its cardiac electrophysiology (EP) lab to p.

Heart Hospital of New Mexico at Lovelace Medical Center and GE HealthCare Collaborate to Install the First Allia IGS Pulse Electrophysiology Lab in the United States for Minimally Invasive Cardiovascular Procedures

CHICAGO--(BUSINESS WIRE)--GE HealthCare, MediView XR, Inc. announce first installation, clinical use of OmnifyXR Interventional Suite at North Star Vascular & Interventional.

GE HealthCare and MediView Announce the World's First Installation and Clinical Use of Augmented Reality Interventional Suite that Aims to Transform the Practice of Interventional Radiology

Medtronic

Zimmer Biomet Hlds

With the growing influence of GenAI in the MedTech sector, innovators like ZBH, GEHC and MDT are poised to thrive.

3 Generative AI-Based MedTech Stocks to Keep an Eye On

GE HealthCare's (GEHC) latest agreement is likely to standardize care protocols and improve the quality of CT, MR and ultrasound examinations.

GE HealthCare's (GEHC) New Tie-Up to Boost Patient Care in Mexico

GE HealthCare Technologies shares have dropped 16.8% since March, driven by concerns about management hitting guidance for 2024. Revenue for the company declined 1.2% in Q1 2024 compared to the same period last year, with a drop in product sales. Despite the recent underperformance, the stock is still considered cheap and may warrant a higher price in the future.

Despite Strong Upside, GE HealthCare Warrants A Downgrade On Guidance Concerns

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) announced today that it has named Roland Rott president and CEO of Imaging and Phil Rackliffe president and CEO of Ultrasound and IGT. Both leaders bring to their roles decades of deep experience in healthcare innovation and experience leading global teams in businesses of scale. This also highlights the depth of internal talent that GE HealthCare is building to strengthen focus on delivering for patients and customers. These changes will b.

GE HealthCare Announces Changes in Strategic Leadership and Key Segments to Better Serve Patients and Customers

TORONTO & CHICAGO--(BUSINESS WIRE)--GE HealthCare once again joins the world's top medical and academic institutions at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting to discuss today's healthcare landscape and announce new precision care tools to meet providers' most pressing needs – namely the accessibility of technologies and solutions for the global practice of personalized medicine. More than half of the world's population is underserved and lacks access to es.

GE HealthCare Increases Access to Precision Care Tools, Encouraging the Continued Adoption and Practice of More Personalized Medicine Around the World

MARLBOROUGH, Mass.--(BUSINESS WIRE)--  GE HealthCare Pharmaco-Economic Study Demonstrates Adding Breast Oncology PET Tracer to Standard Workup of Patients with Metastatic or Recurrent Breast Cancer May Yield Beneficial Clinical and Economic Outcomes, Potentially Saving $142M Over Five Years in the US In a GE HealthCare sponsored pharmaco-economic study published in peer-reviewed journal PLOS ONE, the incidence, prevalence, diagnostic pathways, and treatments of different patients with metastati.

GE HealthCare Pharmaco-Economic Study Demonstrates Adding Breast Oncology PET Tracer to Standard Workup of Patients with Metastatic or Recurrent Breast Cancer May Yield Beneficial Clinical and Economic Outcomes, Potentially Saving $142M Over Five

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), a leading medical technology innovator, and Tampa General Hospital (TGH), one of the nation's leading academic health systems, continue to strengthen their long-term partnership by announcing an agreement to deploy GE HealthCare's Imaging and Ultrasound technology solutions to benefit clinicians and patients in TGH Imaging's outpatient facilities across the state of Florida. Both organizations are collaborating to help deliver more precise.

GE HealthCare and Tampa General Hospital Expand Long-Term Partnership to Benefit Patients and Clinicians Across the State of Florida

Abbott Labs

UnitedHealth Group

Healthcare stocks to buy are booming in the U.S. due to the nation's aging population. Spending on healthcare in the U.S. now totals $4.4 trillion, or $13,493 per person, each year — more than any other country on earth.

Wall Street Favorites: 3 Healthcare Stocks With Strong Buy Ratings for May 2024

NCR Atleos Corp

NEXTracker Inc

Despite being unwanted and unloved, spinoff stocks are often excellent stocks to buy and hold. Since investors bought shares in the parent company, they are often not interested in the business.

Spinoff Speed Demons: How Much Further Can These 3 Stocks Run?

CHICAGO--(BUSINESS WIRE)--GE HealthCare has topped a U.S. Food and Drug Administration (FDA) list of artificial intelligence (AI) enabled medical devices for the third year in a row with 72 listed 510(k) clearances or authorizations to date in the United States. GE HealthCare also topped the list when it was updated by the FDA in 2022 and 2023. Central to the company's strategy, GE HealthCare is investing in AI and machine learning to power its vision of enabling precision care. Precision care.

GE HealthCare Tops List for Third Year in a Row with Highest Number of AI-Enabled Medical Device Authorizations

GE HealthCare (GEHC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

GE HealthCare Technologies Inc. (GEHC) is Attracting Investor Attention: Here is What You Should Know

GE HealthCare (GEHC) and Medis Medical collaborate to boost precision care for coronary artery disease treatment.

GE HealthCare (GEHC), Medis Medical Partner to Aid CAD Therapy

CHICAGO--(BUSINESS WIRE)--Today, GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, and Medis Medical Imaging, a leading cardiac imaging software company, announced their collaboration aimed at helping advance precision care in the diagnosis and treatment of coronary artery disease (CAD). Together, the two companies will work to further the development and commercialization of Medis Quantitative Flow Ratio (Medis QFR),.

GE HealthCare and Medis Medical Imaging Announce Collaboration Focused on Non-Invasive Coronary Assessments to Help Advance Precision Care in Treatment of Coronary Artery Disease

GE HealthCare (GEHC) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

GE HealthCare Technologies Inc. (GEHC) Is a Trending Stock: Facts to Know Before Betting on It

GE HealthCare's (GEHC) new SIGNA MAGNUS can delve deep into the brain's microstructure, microvasculature and function, providing researchers with a clearer picture of neurological diseases and disorders.

GE HealthCare (GEHC) Unveils Head-Only MR Scanner SIGNA MAGNUS

GE HealthCare Technologies Inc. expects revenue growth to recover in the second half of 2024, driven by easing year-over-year comparisons and a rebound in Chinese sales.

GE HealthCare: A Good Buy At Current Levels

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), a leader in precision care innovation, will host an investor day on Thursday, November 21, 2024, in New York, NY. GE HealthCare's management team will present its growth strategies, technology portfolio, and vision for its businesses via a live webcast and will be accessible at https://investor.gehealthcare.com/news-events/events. More information, including registration details, will be available as the date draws closer. About GE HealthC.

GE HealthCare to Hold an Investor Day in New York City on November 21, 2024

Kenvue

Solventum Corporation

There's a lot of evidence suggesting that spinoff stocks are generally a good idea to watch. Following a split from their parent company, many such firms do well thanks to their efficiency and newly-found flexibility.

Investor Alert: Are These 3 Spinoff Stocks Destined to Sizzle or Fizzle?

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today unveiled SIGNA MAGNUS, an FDA 510(k) pending head-only magnetic resonance (MR) scanner designed to explore advancements in neuroscience, which have been restricted by the performance limitations of conventional whole-body MR systems. Neuroscience, particularly in the study of psychiatric diseases and neurological disorders such as Alzheimer's, has been constrained by technological and biological limitations, leaving many aspects of th.

Pushing the Boundaries of Neuroscience with GE HealthCare's SIGNA MAGNUS

The company remains on track for growth in 2024. Management believes new product introductions will drive growth and margin expansion.

Why Shares in GE Healthcare Looked Sick This Week

GE Healthcare (GEHC) unveils Revolution RT, along with other upgrades, from its portfolio during the ESTRO 2024 Congress.

GE Healthcare's (GEHC) Revolution RT to Aid Cancer Treatment

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), is announcing that its Vice President and Chief Financial Officer, Jay Saccaro will be presenting at the following upcoming investor conferences. Bank of America Securities 2024 Healthcare Conference in Las Vegas – May 14, 2024 at 1:00 pm ET/10:00 am PT Jefferies Global Healthcare Conference in New York – June 5, 2024 at 10:00 am ET These events can be accessed at the GE HealthCare website: https://investor.gehealthcare.com/news-events/eve.

GE HealthCare Management to Present at Upcoming Investor Conferences

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced Revolution RT,i a new radiation therapy computed tomography (CT) solution with innovative hardware and software solutions to help increase imaging accuracy, while simplifying simulation workflow for a more personalized and seamless oncology care pathway experience for clinicians and patients. The new Revolution RT is being unveiled at the European Society for Therapeutic Radiology and Oncology (ESTRO) 2024 Congress in Glasgo.

News for GE HealthCare Technologies Inc Stock (GEHC)